Periodic Reporting for period 1 - iMoHEALTH (iMoHEALTH: A pan-national collaborative analytics platform for the exploration of population health.)
Reporting period: 2014-10-01 to 2015-02-28
Phase one of the project has explored technical, business and operational issues associated with developing a pan-national collaborative analytics platform for the exploration of population health.
Results are as follows:
• Data availability. Data is available with the European market moving relatively slowly towards the processing of very high data volumes. Institutions currently find it difficult to manage complex clinical data involving tens of thousands of patients.
• Cloud scale and hosting. The hosting requirements for iMoHEALTH are very reasonable for an enterprise level product and at the current data volumes, data costs are not significant.
• Information security. Analysis of iMoHEALTH requirements did not identify any major features not already supported. However, iMoHEALTH should assuage concerns regarding security risks through continued documented internal secure development and testing practices, and through extensive security testing conducted by a reputable security testing organisation.
• Data loading. The distributed architecture which would form the basis for iMoHEALTH is sufficient to deal with the user base and datasets that have been identified. The performance of the system requires further work to make iMoHEALTH better performing for organisations with datasets containing greater than 1 million patients.
• Market research and competitive analysis. A thorough assessment of potential markets was conducted. Overall, no other product comes close to iMoHEALTH in supporting collaborative and extensive exploration of complex data such as is now required for both research and quality improvement purposes.
• Route to market. The most attractive options appear to be sales to healthcare providers, research groups, NCRBs and licensing to Electronic Health Records companies.
• Sales cycle. The length of the sales cycle in each market segment has been verified in order to enable accurate prediction of revenue growth.
• Development requirements. Essential and additional product requirements have been identified.
• Data availability. Data is available with the European market moving relatively slowly towards the processing of very high data volumes. Institutions currently find it difficult to manage complex clinical data involving tens of thousands of patients.
• Cloud scale and hosting. The hosting requirements for iMoHEALTH are very reasonable for an enterprise level product and at the current data volumes, data costs are not significant.
• Information security. Analysis of iMoHEALTH requirements did not identify any major features not already supported. However, iMoHEALTH should assuage concerns regarding security risks through continued documented internal secure development and testing practices, and through extensive security testing conducted by a reputable security testing organisation.
• Data loading. The distributed architecture which would form the basis for iMoHEALTH is sufficient to deal with the user base and datasets that have been identified. The performance of the system requires further work to make iMoHEALTH better performing for organisations with datasets containing greater than 1 million patients.
• Market research and competitive analysis. A thorough assessment of potential markets was conducted. Overall, no other product comes close to iMoHEALTH in supporting collaborative and extensive exploration of complex data such as is now required for both research and quality improvement purposes.
• Route to market. The most attractive options appear to be sales to healthcare providers, research groups, NCRBs and licensing to Electronic Health Records companies.
• Sales cycle. The length of the sales cycle in each market segment has been verified in order to enable accurate prediction of revenue growth.
• Development requirements. Essential and additional product requirements have been identified.
A business plan has been developed which includes potential sources of funding, routes to market and marketing. In terms of IPR strategy, the company has been granted 2 patents related to the platform and 7 further patent applications are pending covering a wide range of enhancements of the technology. A review from the firm’s patent lawyers confirms freedom to operate. The response from test centres has been overwhelmingly positive.